* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Dish of the Day
Admissions:
None
Delistings:
None
What's baking in the oven "new today?"
None
Banquet Buffet****
London Stock Exchange: Main Market and AIM
EnergyPathways 6.85p £16.61m (EPP.L)
The energy transition Company has selected Jacobs (NYSE:J) to provide planning, regulatory, consenting and environmental services for its proposed Long Duration Energy Storage (LDES) project in the Irish Sea and Barrow-in-Furness. This includes assisting the Company in its submission to Ofgem's forthcoming LDES Cap and Floor round. MESH, designated as a project of national significance by the UK Government, is positioned to become the UK's largest long-duration energy storage project at 300MW / 55 GWh / 100+hours duration. EnergyPathways' bespoke design is expected to provide substantial "total system benefits" to the UK's electricity grid.
Ferrexpo 33.10p £174.66m (FXPO.L)
The producer and exporter of premium iron ore products announces that it has entered into a loan agreement with Fevamotinico S.à r.l., the Company's largest shareholder, pursuant to which Fevamotinico will make available an unsecured loan facility to the Company in the principal amount of US$15m. The Loan is intended to provide the Company with immediate access to liquidity ahead of completion of the approximately US$100m fundraising announced by the Company on 4 September, and to support the Company's working capital requirements and the Group's production operations that restarted as announced on 7 September. The Loan represents a pre-payment of part of Fevamotinico's approximately US$40m subscription under the Fundraise.
Flowtech Fluidpower 67.00p £55.38m (FLO.L)
The supplier of supplier of technical fluid power products delivered a first-half performance in line with the Board's expectations. Like-for-like revenue grew 13.3%, strongly ahead of H1 25, and total revenue rose 23.8% to £70.4m (H1 25: £56.9m), supported by recent acquisitions and market share gains across all three regions. The Company acted quickly to mitigate supply-chain disruption and inflationary pressure from the Middle East conflict, protecting product availability, customer service and managing gross margins. The self-help growth initiatives have strengthened the H2 sales pipeline and order book, with significant profit and cash contribution expected from the two major bridge contracts.
Gem Resources 0.40p £4.21m (GEMR.L)
The natural resources Company focused on identifying, acquiring and advancing value-accretive mining and resource opportunities announced that its Hong Kong subsidiary, GemR Corporation Limited, has entered into a conditional share purchase agreement to acquire 100% of the issued share capital of CREC Material Co S.A.S. for an all-share consideration of £750k. CREC is the Colombian company through which the El Yarumo gold processing operation in Buenos Aires, Cauca is conducted. The acquisition remains subject to satisfaction (or waiver) of certain conditions precedent and has not yet completed.
Inspiration Healthcare Group 20.50p £16.59m (IHC.L)
The global medical technology Company pioneering specialist neonatal intensive care medical devices provides a trading update for the six months ended 31 July 2026. Revenue for the period was £22m (H1 FY26: £24m) with the prior period benefitting from significant one-off contract revenues of £6.5m. Against this backdrop, the Group delivered strong underlying growth primarily led by its SLE product portfolio. Excluding one-off revenues from the prior year, SLE product revenues increased to £12.7m which represents an increase of 38% over H1 FY26, demonstrating continued demand for the Group's core neonatal intensive care products and further progress towards the strategy to double SLE revenues. Airon also performed strongly in the period, with revenues growing by 40% to £1.6m following the initial order under the three-year purchasing agreement with a large US healthcare provider.
Manolete Partners 39.00p £16.27m (MANO.L)
The insolvency claims financing Company provided an update on trading in the current financial year (FY27) ahead of its AGM today. The trading performance has been positive and in-line with the Board's expectations for FY27. Realised revenues are ahead of the prior year, and the value of the forward book has continued to increase, driven by growth in both the number and average value of new cases signed. A more detailed update on trading for H1 will be provided in early October following the first half end, and Manolete will announce its Half Year Results as usual in November.
Novacyt 45.00p £30.82m (NCYT.L)
The international molecular diagnostics Company with a growing portfolio of integrated technologies and services announces the commercial launch of the In Vitro Diagnostic Regulation (IVDR)-certified Yourgene Insight DPYD assay, expanding the Company's clinical genetics portfolio across regulated European markets. The launch follows the successful introduction of the Yourgene Insight DPYD assay as a Research Use Only product in May 2026 and marks the completion of the assay's regulatory transition to full compliance with the European Union's IVDR. The Yourgene Insight DPYD assay enables the accurate detection of 19 clinically relevant variants in the DPYD gene, supporting the identification of patients at increased risk of severe toxicity from fluoropyrimidine-based chemotherapy. The assay provides laboratories and clinicians with an important tool to support informed treatment decisions and improve patient management.
Trifast 84.80p £117.67m (TRI.L)
The international specialist in the design, engineering, manufacture, and distribution of high-quality engineered fastenings provided a trading update in advance of the AGM today. Trading in the current financial year remains in line with market expectations, (revenue of £214m and adjusted EBIT of £18.6m), notwithstanding a challenging macroeconomic backdrop. Trifast remains focused on execution of its strategic priorities, continued margin improvement and cash generation, while maintaining close control of costs. The Board remains confident in the medium-term prospects and in the continued progress being made under its Recover, Rebuild, Resilience strategy. A further update will be provided in the pre-close half year results trading update expected to be released on 20 October.
Serval Resources 32.50p £11.18m (SRVL.L)
The Company focused on building an independent copper and future metals developer provided an update on its work programme for the Kaoko Basin project in Namibia. The completion of a geological mapping campaign confirmed previously identified and drilled Cu-mineralisation across the EPL 7081 area, specifically the Omatapati and Otjozongombe prospects. More Cu-mineralisation in surface samples was identified in areas not previously known. These new discoveries of Cu-mineralisation at surface are along strike of known Cu-mineralisation, indicating an increase in the potential strike length and size of the potential Cu-deposits.
Xeros Technology Group 1.13p £11.64m (XSG.L)
The creator of technologies that reduce the impact of clothing on the planet announces its unaudited interim results for the six months ended 30 June 2026. The results show good operational progress and continued industry impact. Revenues increased by 67.7% to £0.1m (H1 2025: £0.1m) as revenue recorded across all the Group's technology areas, while the adjusted EBITDA loss remained static at £1.6m (H1 2025: £1.6m). Net cash at 30 June 2026 was £3.5m (2025: £1.2m), with cash at the end of August at £2.8m, while the Group remains debt free. Wider appliance industry headwinds including pressure from lower cost competition impacting US and European OEMs are extending programme timelines beyond the Company’s control and likely to push early revenues anticipated in H2 of the current year into H1 2027.
What’s baking in the oven?
Potential IPOs:***
5th August: 1947 Oil & Gas, the newly incorporated oil and gas production Company focused on acquiring, operating and growing a portfolio of producing assets in the US, announced its intention to IPO onto AIM. In connection with Admission, the Company has entered into a conditional agreement to acquire Renaissance Offshore, LLC, a privately held, Houston-based oil and gas production Company with interests in eleven fields located in the shallow-water Gulf of America. The Company is raising an updated amount of £40m and the expected market capitalisation of the Company on Admission will be £70m. Admission is expected to occur in mid-September, updated from an expected date of in August.
Dual List:***
18th August: Aimia Inc. (TSX: AIM; JSE: AII) the Canadian diversified conglomerate announced plans to dual list on AIM. It owns a selection of businesses which include: (i) an 100% interest in Cortland International Inc., a global designer, manufacturer and supplier of synthetic fiber ropes, nets, slings and tethers; a 10.85% indirect stake in Clear Media Limited, the largest operator of bus shelter advertising panels in China; and iii) the Company holds a portfolio of publicly listed securities amounting C$12m as of 30 June 2026. No capital is expected to be raised on Admission and deal details remain TBC. Expected first day of dealings 9th September.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
